Sumitomo Pharma America, Inc.

Sumitomo Pharma America (SMPA) is deeply committed to accelerating scientific and therapeutic breakthroughs to support patient-first outcomes in areas of critical need, including psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies. SMPA aims to address a wide range of indications where treatment options remain limited or nonexistent. By doing so, we strive to make a significant impact on patients’ lives and well-being. Our diverse portfolio includes several marketed products and a robust pipeline of early- to late-stage assets.

SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliates. Our parent company, the Sumitomo Group, is over 400 years old, with an extensive history of supporting health and wellbeing. SMPA is a Sumitomo Pharma company.

and SUMITOMO PHARMA are trademarks of Sumitomo Pharma Co., LTD., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co. Ltd.

©2024 Sumitomo Pharma America, Inc. All rights reserved. 04/24 PP-US-REL-2400052

Sumitomo Pharma America Oncology Product

• ORGOVYX (relugolix)

Other Sumitomo Pharma America Products

• https://www.us.sumitomo-pharma.com/products/

ORGOVYX® and its associated logo are trademarks of Myovant Sciences GmbH. and SUMITOMO PHARMA are trademarks of Sumitomo Pharma Co., LTD., used under license. SUMITOMO is a registered trademark of Sumitomo Chemical Co., Ltd., used under license. Sumitomo Pharma America, Inc. is a U.S. subsidiary of Sumitomo Pharma Co. Ltd.

©2024 Sumitomo Pharma America, Inc. All rights reserved. 04/24 PP-US-REL-2400052